PMID- 12579257
OWN - NLM
STAT- MEDLINE
DCOM- 20030729
LR  - 20141120
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 10
IP  - 2
DP  - 2003 Mar-Apr
TI  - Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular 
      carcinoma.
PG  - 271-6
AB  - Dihydrodiol dehydrogenase (DDH) is one of the major enzymes catabolizing 
      polycyclic aromatic hydrocarbons in the liver. Although four DDH isoforms have 
      been detected in the normal liver, only DDH1 and DDH2 have been detected in 
      cancer cells of lung and esophagus. Moreover, the available information about 
      hepatic pathophysiological regulation of DDH expression is limited. Therefore we 
      addressed the question of DDH expression in patients with liver disorders, in 
      particular, patients with hepatocellular carcinoma (HCC). Expression of DDH1/2 
      was determined by immunohistochemistry, immunoblotting and reverse 
      transcription-polymerase chain reaction (RT-PCR) in 52 patients with resected 
      HCC. DDH1/2 expression was detected in 31 (59.6%) of 52 pathological sections. 
      Frequency of DDH1/2 expression was significantly higher in patients with tumor 
      size >2 cm, and in those who had early local recurrence. In addition to the tumor 
      size and frequency of local recurrence, our results further indicated that 
      expression of DDH1/2 was correlated with those of cyclooxygenase 2 (COX-2), 
      interleukin-6 (IL-6), microsomal epoxide hydrolase (mEpH) and soluble epoxide 
      hydrolase (sEpH) in HCC patients. Interestingly, the expression of DDH1/2 was 
      found inversely correlated with that of glutathione S-transferase (GST) and NADPH 
      p450 reductase (NPR). In conclusion, these results indicate that DDH expression 
      was significantly decreased in about 40% of HCC patients. However, in the 
      bordering non-neoplastic region of liver DDH1/2 expression increased, and the 
      increased DDH1/2 expression correlated with tumor size and the disease 
      progression.
FAU - Yang, Mei-Due
AU  - Yang MD
AD  - Department of Surgery, China Medical College Hospital and Institute of Medical 
      Science, China Medical College, Taichung, Taiwan.
FAU - Wu, Cheng-Chung
AU  - Wu CC
FAU - Chiou, Shiow-Her
AU  - Chiou SH
FAU - Chiu, Chang-Fang
AU  - Chiu CF
FAU - Lin, Tze-Yi
AU  - Lin TY
FAU - Chiang, I-Ping
AU  - Chiang IP
FAU - Chow, Kuan-Chih
AU  - Chow KC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (DNA Primers)
RN  - 0 (Interleukin-6)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.- (Oxidoreductases)
RN  - EC 1.14.13.- (Cytochrome P-450 CYP2E1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 1.3.1.20 (trans-1,2-dihydrobenzene-1,2-diol dehydrogenase)
RN  - EC 1.6.2.4 (NADPH-Ferrihemoprotein Reductase)
RN  - EC 2.5.1.18 (Glutathione Transferase)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
SB  - IM
MH  - Carcinoma, Hepatocellular/*enzymology/pathology/surgery
MH  - Cell Differentiation
MH  - Cyclooxygenase 2
MH  - Cytochrome P-450 CYP2E1/metabolism
MH  - DNA Primers/chemistry
MH  - Down-Regulation
MH  - Epoxide Hydrolases/metabolism
MH  - Female
MH  - Glutathione Transferase/metabolism
MH  - Hepatitis/enzymology/pathology
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Interleukin-6/metabolism
MH  - Isoenzymes/metabolism
MH  - Liver/enzymology
MH  - Liver Cirrhosis/enzymology/pathology
MH  - Liver Neoplasms/*enzymology/pathology/surgery
MH  - Male
MH  - Membrane Proteins
MH  - Middle Aged
MH  - NADPH-Ferrihemoprotein Reductase/metabolism
MH  - Oxidoreductases/genetics/*metabolism
MH  - Prostaglandin-Endoperoxide Synthases/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2003/02/13 04:00
MHDA- 2003/07/30 05:00
CRDT- 2003/02/13 04:00
PHST- 2003/02/13 04:00 [pubmed]
PHST- 2003/07/30 05:00 [medline]
PHST- 2003/02/13 04:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2003 Mar-Apr;10(2):271-6.